Literature DB >> 28019140

Cutaneous mucormycosis as result of insulin administration in an AML patient: Case report and review of the literature.

Anke Delie1, Philip Vlummens1, David Creytens2, Eva Steel1.   

Abstract

We present a case of cutaneous mucormycosis in a patient with several important risk factors precipitating disease, namely underlying acute myeloid leukaemia and poorly controlled secondary diabetes. Inoculation was most likely caused by repeated minor trauma (insulin injection) at the site of infection. Treatment consisted of surgical debridement and liposomal Amphotericin B (LAmB) during 71 days. Posaconazole had already been initiated prior to infection as primary antifungal prophylaxis but was discontinued during follow-up as susceptibility testing later revealed resistance to posaconazole. Additional treatment with caspofungin and G-CSF was associated because of poor initial result to treatment. Caspofungin was later continued as monotherapy when LAmB had to be interrupted because of renal toxicity. Treatment was completed after closure of the surgical site. The patient was successfully treated and remains infection free for one year after initial diagnosis.

Entities:  

Keywords:  Acute myeloid leukaemia; Diabetes; Mucomycosis; Rhizopus microsporus; Zygomycosis

Mesh:

Substances:

Year:  2016        PMID: 28019140     DOI: 10.1080/17843286.2016.1266802

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  2 in total

Review 1.  A Guide to Investigating Suspected Outbreaks of Mucormycosis in Healthcare.

Authors:  Kathleen P Hartnett; Brendan R Jackson; Kiran M Perkins; Janet Glowicz; Janna L Kerins; Stephanie R Black; Shawn R Lockhart; Bryan E Christensen; Karlyn D Beer
Journal:  J Fungi (Basel)       Date:  2019-07-24

2.  Primary cutaneous mucormycosis of the abdomen at the site of repeated insulin injections.

Authors:  Allison Perz; Gabriel Makar; Edward Fernandez; Joshua Weinstock; William Rafferty
Journal:  BMJ Case Rep       Date:  2020-02-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.